-

Viz.ai Honored by Goldman Sachs for Entrepreneurship

CEO Chris Mansi Recognized Among the Most Exceptional Entrepreneurs, 2023 Builders and Innovators

SAN FRANCISCO--(BUSINESS WIRE)--Today, Goldman Sachs (NYSE:GS) is recognizing Viz.ai CEO and Co-founder Chris Mansi, MD as one of the Most Exceptional Entrepreneurs of 2023 at its Builders and Innovators Summit in Healdsburg, California. Goldman Sachs selected Dr. Mansi from multiple industries to be honored at the two-day event.

Dr. Chris Mansi was inspired by a patient who underwent a successful brain surgery and yet died because the surgery came too late. Frustrated by the unnecessary delays that had cost his patient her life, he committed to finding a better way. In 2016, Dr. Mansi joined forces with Dr. David Golan to co-found Viz.ai, establishing its mission to increase access to life-saving treatments using artificial intelligence. Under Chris’ leadership, Viz.ai was granted the first de novo approval by the FDA for AI computer-aided triage in 2018 and again in 2023 for cardiovascular machine learning-based notification software. Today, Viz.ai is implemented in over 1,450 hospitals covering 220 million lives and collaborates with 7 of the leading, global pharmaceutical and medical device companies to help detect disease earlier and direct patients to the right specialists.

“I am honored to be recognized by Goldman Sachs for entrepreneurship alongside such esteemed, visionary leaders,” said Chris Mansi. “It’s a testament to the dedication and hard work of the Viz.ai team, always putting patients first as we continue to innovate on the Viz.ai platform. I’m incredibly proud of the real-world impact that we have made by transforming healthcare and partnering with major pharmaceutical and medical device companies in service of better patient outcomes.”

“We’re delighted to recognize Chris Mansi as one of the most exceptional entrepreneurs of 2023,” said David Solomon, Chairman and CEO of Goldman Sachs. “Like everyone in this year’s class, Chris has been a visionary in their field, pushing forward innovation and redefining markets. We are excited to harness Goldman’s convening power to bring together these dynamic leaders and hear their insights.”

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 220 million lives across 1,450+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz.ai Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

About Goldman Sachs

Goldman Sachs is a leading global financial institution that delivers a broad range of financial services to a large and diversified client base that includes corporations, financial institutions, governments and individuals. Founded in 1869, the firm is headquartered in New York and maintains offices in all major financial centers around the world.

Contacts

Ariane Lovell
ariane.lovell@finnpartners.com

Press related questions about the Summit or Goldman Sachs, please contact Sophia Anthony at Sophia.Anthony@gs.com.

Viz.ai


Release Versions

Contacts

Ariane Lovell
ariane.lovell@finnpartners.com

Press related questions about the Summit or Goldman Sachs, please contact Sophia Anthony at Sophia.Anthony@gs.com.

Social Media Profiles
More News From Viz.ai

A Decade of Increasing Access to Life Saving Treatments: Viz.ai Celebrates 10 Years, 2,000 Hospitals, and 230 Million Patients

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today celebrates its 10th anniversary, marking a decade of transforming how healthcare teams deliver care for patients. The company launched in 2016 to solve a key problem: variability in healthcare means that many patients fail to get guideline based care, even in life threatening diseases like stroke. Since achieving the first FDA clearance for an AI platform and increasing tr...

Viz.ai to Support the MINUTE Trial, a Landmark Multicenter Study Evaluating the SCUBA Technique for the Treatment of Intracerebral Hemorrhage

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced its support for the Minimally Invasive Neurosurgery Trial for Ultra-early Treatment (MINUTE) Trial, a prospective, multicenter, randomized study evaluating whether the SCUBA technique, an endoscopic, catheter-based approach for ultra-early evacuation of basal ganglia intracerebral hemorrhage (BGH), is a promising alternative to standard medical management to pote...

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growi...
Back to Newsroom